Want to see AURX full AI Analyst Report?
Total Valuation
Nuo Therapeutics has a market cap or net worth of $50.70M. The enterprise value is $47.83.
Market Cap$50.70M
Enterprise Value$47.83
Share Statistics
Nuo Therapeutics has 48,433,777 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,433,777
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Nuo Therapeutics’s return on equity (ROE) is 2.63 and return on invested capital (ROIC) is -408.69%.
Return on Equity (ROE)2.63
Return on Assets (ROA)-1.36
Return on Invested Capital (ROIC)-408.69%
Return on Capital Employed (ROCE)-4.67
Revenue Per Employee331.35K
Profits Per Employee-251.22K
Employee Count10
Asset Turnover1.80
Inventory Turnover5.13
Valuation Ratios
The current PE Ratio of Nuo Therapeutics is ―. Nuo Therapeutics’s PEG ratio is -10.00.
PE Ratio―
PS Ratio28.13
PB Ratio-97.44
Price to Fair Value-97.44
Price to FCF-81.78
Price to Operating Cash Flow-24.09
PEG Ratio-10.00
Income Statement
In the last 12 months, Nuo Therapeutics had revenue of 3.31M and earned -2.51M in profits. Earnings per share was -0.05.
Revenue3.31M
Gross Profit2.22M
Operating Income-2.52M
Pretax Income-2.51M
Net Income-2.51M
EBITDA-2.36M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -2.15M and capital expenditures -297.08K, giving a free cash flow of -2.45M billion.
Operating Cash Flow-2.15M
Free Cash Flow-2.45M
Free Cash Flow per Share-0.05
Dividends & Yields
Nuo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.79
52-Week Price Change-34.36%
50-Day Moving Average0.96
200-Day Moving Average1.44
Relative Strength Index (RSI)59.74
Average Volume (3m)2.99K
Important Dates
Nuo Therapeutics upcoming earnings date is Aug 17, 2026, TBA (Not Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Nuo Therapeutics as a current ratio of 1.06, with Debt / Equity ratio of -97.46%
Current Ratio1.06
Quick Ratio0.89
Debt to Market Cap<0.01
Net Debt to EBITDA-0.02
Interest Coverage Ratio-3.13K
Taxes
In the past 12 months, Nuo Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nuo Therapeutics EV to EBITDA ratio is -39.52, with an EV/FCF ratio of -81.82.
EV to Sales28.14
EV to EBITDA-39.52
EV to Free Cash Flow-81.82
EV to Operating Cash Flow-107.81
Balance Sheet
Nuo Therapeutics has $449.32K in cash and marketable securities with $1.50M in debt, giving a net cash position of -$1.05M billion.
Cash & Marketable Securities$449.32K
Total Debt$1.50M
Net Cash-$1.05M
Net Cash Per Share-$0.02
Tangible Book Value Per Share-$0.02
Margins
Gross margin is 64.11%, with operating margin of -75.95%, and net profit margin of -75.82%.
Gross Margin64.11%
Operating Margin-75.95%
Pretax Margin-75.82%
Net Profit Margin-75.82%
EBITDA Margin-71.21%
EBIT Margin-75.95%
Analyst Forecast
The average price target for Nuo Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast166.61%
EPS Growth Forecast21.09%